Updated:
Secura Bio
Secura Bio was founded in 2019 by Juan Estruch, who previously held senior corporate development roles at Ciba-Geigy, Novartis, and Genoptix.
Secura Bio
Secura Bio was founded in 2019 by Juan Estruch, who previously held senior corporate development roles at Ciba-Geigy, Novartis, and Genoptix. The firm operates from offices in Berkeley Heights, New Jersey; Dublin, Ireland; and Las Vegas, Nevada. Its leadership draws heavily from the commercial teams at Seagen (acquired by Pfizer), Celgene (acquired by Bristol Myers Squibb), and Genentech — signaling a deep bench in oncology product launches. The firm's strategy centers on acquiring or licensing oncology assets that are underperforming or underexploited, then applying a high-touch commercial model to optimize their market position. Its leadership has generated billions in value through strategic commercialization and acquisitions (per the firm). Asset classes include direct investment in marketed therapies, product acquisitions, and licensing deals. The team has particular experience with antibody-drug conjugates, leukemia/lymphoma treatments, and cell therapies. Geographic focus spans the U.S. and Europe. The firm has not disclosed its AUM or total deployment. The board includes Jeffrey A. Ferrell, founder of Athyrium Capital Management, and Patrick Vink, who was COO of Cubist before its $9.5B sale to Merck. Secura Bio does not appear to have an active news cycle in the last 24 months — its website lists recent news but none dated after 2023 (per firm website, 2023). A structural differentiator is its pure-play focus on oncology commercial execution without a pipeline of internally discovered assets. Secura Bio acts as an operating company that acquires and revitalizes late-stage or approved therapies — a niche between a pharmaceutical company and an investment firm. The board's mix of life-sciences investors (Ferrell) and former pharma operators (Vink, Moeller) reinforces this hybrid posture.
General information
Firm type
Asset Manager
Year founded
2019
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Berkeley Heights
Corporate office
Berkeley Heights, New Jersey, United States
Additional offices
Dublin, Ireland · Las Vegas, United States
Principals
Juan Estruch
Co-Founder
Chip R. Romp
Executive Vice President, US Commercial (former Seagen)
Will Brown
Chief Financial Officer
Gregory S. Wessels
Chief Commercial Officer
Christiane Langer
Senior Vice President, Global Medical Affairs
Cari Barthe
Director of People and Culture
Patrick Vink
Chairman of the Board
Jeffrey A. Ferrell
Board Member
Joerg Moeller
Board Member
Sector focus
Frequently asked questions
Who started Secura Bio and what is the background of its leadership?
The firm was co-founded in 2019 by Juan Estruch, who has over 25 years in life sciences corporate development at Novartis, Ciba-Geigy, and Genoptix. The board is chaired by Patrick Vink, former COO of Cubist, and includes Jeffrey A. Ferrell, founder of Athyrium Capital Management (per the firm's website).
How does Secura Bio differ from a traditional pharmaceutical company?
Secura Bio does not invest in early-stage drug discovery. Instead, it acquires or licenses approved or late-stage oncology therapies and applies a specialized commercial team to maximize their market potential. This operating-company model sits between a pharmaceutical company and an investment firm.
Does Secura Bio disclose its AUM or investment returns?
The firm does not publicly disclose AUM, deployment size, or portfolio returns. Its website focuses on the team's track record at prior companies rather than its own capital base (per firm website, 2025).
What types of deals does Secura Bio target?
Secura Bio targets under-exploited oncology therapies — typically marketed or late-stage assets that need repositioning or relaunch. It does not appear to participate in early-stage venture funding or public equity investments (per firm website).
Is Secura Bio structured as a family office?
Secura Bio presents itself as a commercial-stage pharmaceutical company, not a family office. Its leadership includes operating and board backgrounds from the biopharma industry. No family office affiliation is disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: